

Elena Fogari

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6915607/elena-fogari-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

1,902
citations

27
h-index

41
g-index

69
ext. papers

2,027
ext. citations

4
avg, IF

3.91
L-index

#	Paper	IF	Citations
67	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. <i>Clinical Therapeutics</i> , 2004 , 26, 744-54	3.5	127
66	Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. <i>Hypertension Research</i> , 2007 , 30, 111-7	4.7	101
65	Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 46-50	3.1	89
64	Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. <i>Clinical Therapeutics</i> , 2004 , 26, 1228-36	3.5	74
63	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , 2013 , 36, 914-20	5.1	71
62	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , 2005 , 69, 5-13	7.4	70
61	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , 2011 , 666, 251-6	5.3	57
60	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , 2007 , 22, 361-70	2.1	55
59	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012 , 98, 51-60	7.4	54
58	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. <i>Hypertension Research</i> , 2007 , 30, 387-94	4.7	52
57	Serum testosterone levels and arterial blood pressure in the elderly. <i>Hypertension Research</i> , 2005 , 28, 625-30	4.7	49
56	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 553-64	4.9	43
55	Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. <i>Hypertension Research</i> , 2005 , 28, 209-14	4.7	43
54	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010 , 57, 777-86	2.9	42
53	Vildagliptin added to metformin on β cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 475-84	8.1	41
52	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011 , 651, 240-50	5.3	41
51	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1495-506	5.4	37

50	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009 , 24, 204-10	2.1	37
49	Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. <i>American Journal of Hypertension</i> , 2007 , 20, 417-22 ³	2.3	37
48	Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. <i>Clinical Therapeutics</i> , 2005 , 27, 1383-91	3.5	36
47	Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. <i>American Journal of Hypertension</i> , 2004 , 17, 823-7	2.3	36
46	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 817-22	2.8	35
45	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009 , 32, E124-32	0.9	32
44	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011 , 34, 145-51	4.7	31
43	Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. <i>Clinical Therapeutics</i> , 2007 , 29, 413-8	3.5	30
42	Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. <i>Current Therapeutic Research</i> , 2000 , 61, 850-862	2.4	30
41	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 45-51		29
40	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1971-82	4	25
39	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010 , 80, 110-5	3.7	24
38	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 957-67	12.7	23
37	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , 2014 , 28, 221-9	3.1	23
36	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , 2013 , 52, 2179-87	1.1	23
35	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 642-51	3.1	22
34	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010 , 79, 144-9	3.7	22
33	Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 271-5	2.8	22

32	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010 , 33, 790-5	4.7	21
31	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2581-91	4	21
30	Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , 2007 , 46, 1837-46	4.1	20
29	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2007 , 29, 602-10	3.5	20
28	Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , 2013 , 33, 817-26	5.8	19
27	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β cell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2433-42	4	18
26	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011 , 113, 950-960	3	16
25	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , 2008 , 39, 412-9	6.6	15
24	A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. <i>Current Therapeutic Research</i> , 2000 , 61, 669-679	2.4	15
23	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 214-22	8.1	14
22	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013 , 91, 724-32	2.4	14
21	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 723-33	7.5	14
20	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2008 , 57, 1552-7	12.7	14
19	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1113-22	2.2	12
18	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 175-83		11
17	Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. <i>Current Therapeutic Research</i> , 2002 , 63, 1-14	2.4	10
16	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012 , 59, 611-9	2.9	9
15	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <i>Clinical Drug Investigation</i> , 2006 , 26, 529-39	3.2	9

14	Effect of manidipine as compared to atenolol on platelet aggregation in elderly patients with isolated systolic hypertension and type II diabetes mellitus. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 45, 310-3	3.1	9
13	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 32-9		7
12	Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus. <i>Current Therapeutic Research</i> , 2000 , 61, 163-173	2.4	7
11	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , 2014 , 37, 154-62	5.1	5
10	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 422-8		5
9	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , 2013 , 35, 301-7	2.2	5
8	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , 2009 , 56, 571-8	2.9	5
7	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 621-9	4.1	4
6	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 47-52	2.9	2
5	Retraction notice to "Evaluation of the positive effects on insulin-resistance and Ecell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. <i>Pharmacological Research</i> , 2017 , 121, 255	10.2	1
4	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1248	3.2	
3	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
2	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
1	Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 123, 584	5.1	